natgillin/translations-raw huggingface dataset:
A process according to claim 13, wherein the acid used in step d) is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, acetic acid, L-tartaric acid, citric acid, L-lactic acid, maleic acid, fumaric acid, succinic acid, methanesulfonic acid, benzenesulfonic acid, benzoic acid, p-toluenesulfonic acid, oxalic acid, p-nitrobenzoic acid, salicylic acid or 4-chlorobenzoic acid. 
Postupak prema patentnom zahtjevu od 8 ili 9, naznačen time, da je kiselina koja se koristi u koraku d) klorovodična kiselina, bromovodična kiselina, sumporna kiselina, fosforna kiselina, octena kiselina, L-vinska kiselina, limunska kiselina, L-mliječna kiselina, maleinska kiselina, fumarna kiselina, jantarna kiselina, metansulfonska kiselina, benzensulfonska kiselina, benzojeva kiselina, p-toluensulfonska kiselina, oksalna kiselina, p-nitrobenzojeva kiselina, salicilna kiselina ili 4-klorobenzojeva kiselina, preciznije 4-klorobenzojeva kiselina.
The method according to claim 1, wherein the calcium carbonate comprises ground calcium carbonate, precipitated calcium carbonate, surface-modified calcium carbonate, or any mixture thereof. The method according to claim 1, wherein the calcium carbonate is ground calcium carbonate. 
Površinski obrađeni kalcijev karbonat prema zahtjevu 1, naznačen time da površinski obrađeni kalcijev karbonat sadrži mljeveni kalcijev karbonat i/ili istaloženi kalcijev karbonat i/ili površinski modificiran kalcijev karbonat, poželjno mljeveni kalcijev karbonat.
The aqueous solution is cooled in an ice-bath and acidified to pH 2 using concentrated HCl. 
Vodenu otopinu se ohladi u ledenoj kupelji i zakiseli se na pH 2 upotrebom koncentrirane HC1.
A method of manufacturing a hop containing beverage that is resistant to light induced flavour changes, said method comprising introducing into said hop containing beverage a light stabilising composition containing at least 0.5% by weight, preferably at least 1.0%, by weight of dry matter, of N-heterocyclic substances and wherein the light stabilising composition, if it contains caramelised material, exhibits an absorption ratio A280/560 of at least 80, preferably of at least 250. 
Postupak proizvodnje pića koje sadržava hmelj, koje je otporno na promjene arome inducirane svjetlom, spomenuti postupak je naznačen time, što sadržava uvođenje u spomenuto piće koje sadržava hmelj pripravka za stabiliziranje na svjetlo koji sadržava najmanje 0,5% po masi, poželjno najmanje 1,0%, po masi suhe tvari, N-heterocikličkih tvari i što pripravak za stabiliziranje na svjetlo, ako sadržava karamelizirani materijal, pokazuje apsorpcijski omjer A280/560 Od najmanje 80, poželjno od najmanje 250.
The orally disintegrating solid pharmaceutical composition of claim 35, wherein the excipient is selected from the group consisting of mannitol, xylitol, sorbitol, maltol, maltitol, lactose, sucrose, maltose, cyclodextrin, and combinations thereof. 
Tableta za oralno disperziranje sukladno patentnom zahtjevu 12, naznačeno time da je ekscipijens odabran iz skupine koju čine manitol, ksilitol, sorbitol, maltol, maltitol, laktozu, saharozu, maltozu, i njihove kombinacije.
The aqueous pharmaceutical suspension according to claim 7, wherein the propylparaben, sodium propylparaben, or potassium propylparaben is, by weight/volume (g/100 mL), about 0.014% to about 0.048%. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što propilparaben, natrij-propilparaben ili kalij-propilparaben iznosi, težinski/volumno (g/100 ml), otprilike 0,014 % do otprilike 0,048 %.
The composition of claim 1, wherein the isolated keratin material comprises Y-keratin proteins. 
Sastav u skladu sa zahtjevom 1, naznačen time, što izolirani keratin materijal obuhvaća y-keratin proteine.
In another aspect of the invention, when n is 2 or 3, the first R5 group is suitably at an ortho-position, the second R5 group is suitably at a meta-position and, optionally (when n is 3), the third R5 group is suitably at a para-position on the benzene ring. 
Prema jednom drugom aspektu izuma, kada je n jednak 2 ili 3, prva skupina R> je poželjno na orto- položaju, druga R? skupina je poželjno na meta- položaju i, opcionalno (kada je n jednak 3), treća R> skupina je poželjno na para- položaju benzenskog prstena.
In particular, the combination of an M3 antagonist of the invention with a B2-agonist, such as salmeterol or formoterol, produces significantly and consistently less heart side-effects, such as tachycardia, than a therapeutically equivalent combination of tiotropium bromide with salmeterol or formoterol. 
Osobito kombinacija M3 antagonista sukladno predmetnom izumu s kortikosteroidom poput budesonida ili beklometazona proizvodi znatno i konzistentno povećanje inhibicije kontraktilnog odgovora trahealnog prstena na alergene u usporedbi s terapijski ekvivalentom kombinacijom tiotropij bromida s budesonidom ili beklometazonom.
Even in the case of an acute psychosis, sufferers may seem completely unaware that their vivid hallucinations and impossible delusions are in any way unrealistic. 
Čak i slučaju akutne psihoze, oboljeli mogu biti potpuno nesvjesni da su njihove živahne halucinacije i nemoguće iluzije na bilo koji način nerealne.
exposing a biological sample of the subject to the antibody of claim 1 or claim 6, or an antigen-binding fragment thereof; 
izlaganje biološkog uzorka iz subjekta protutijelu u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 10, ili njegovom antigenski vežućem fragmentu;
The method of claim 1, wherein R1 is The method of claim 1, wherein the compound of formula (II) is 4-chlorophenylacetic acid. 
HR P20130001 T1 Metoda iz bilo kojeg od prethodnih zahtjeva, naznačena time, što je spoj formule (II) 4-klorofeniloctena kiselina.
wherein the container (10) i) covers the connection element (11) and ii) covers and supports the upper distal end of the endless ring defined by the cord (8) and conceals the upper distal end of the endless ring from exterior view, 
Naprava (7) u skladu s patentnim zahtjevom 1, naznačena time što odvajanje navedenog nosača (10) od navedenog spojnog elementa (11) poništava napetost užeta (5).
mixing an unsaturated polyester thermosetting material into a resin paste; 
miješanje nezasićenog poliesterskog termoreaktivnog materijala u pastu od smole (14);
wherein (i) substantial steady-state delivery of the exenatide at a therapeutic concentration is achieved within a time period selected from the group consisting of 5 days or less, 4 days or less, 3 days or less, 2 days or less, and 1 day or less after implantation of the osmotic delivery device in the human, and(ii) the substantial steady-state delivery of the exenatide from the osmotic delivery device is continuous over an administration period of at least 3 months at a mcg/day dose of exenatide selected from the group consisting of 10 mcg/day, 20 mcg/day, 40 mcg/day, 60 mcg/day and 80 mcg/day; and wherein the method further comprises a first continuous administration period of the exenatide at a first mcg/day dose that is followed by a second continuous administration period providing a dose escalation of the exenatide to a second mcg/day dose, wherein the second mcg/day dose is greater than the first mcg/day dose. 
gdje se uglavnom stabilna dostava eksenatida u terapeutskoj koncentraciji, postiže unutar vremenskog perioda odabranog iz skupine koju čine 5 dana ili manje, 4 dana ili manje, 3 dana ili manje, 2 dana ili manje, i 1 dan ili manje, nakon implementiranja osmotskog uređaja za izdavanje kod čovjeka, i (ii) gdje je uglavnom stabilna dostava eksenatida iz osmotskog uređaja za izdavanje, kontinuirana kroz vremenski period primjene koji traje najmanje 3 mjeseca uz dozu eksenatida po ug/dan, koja je odabrana iz skupine koju čine 10 ug/dan, 20 ug/dan, 40 ug/dan, 60 ug/dan i 80 ug/dan; i pritom postupak dodatno obuhvaća prvi kontinuirani vremenski period primjene eksenatida u prvoj dozi eksenatida po ug/dan, a nakon čega slijedi drugi kontinuirani vremenski period primjene eksenatida u kojem se doza povećava na drugu dozu eksenatida po ug/dan, pri čemu je druga doza u ug/dan veća od prve doze u ug/dan.
R16A and R16B are each independently selected from H and an optionally substituted C1-C8 alkyl, or together with the nitrogen to which they are attached form an optionally substituted hetero C3-C10 cycloalkyl, wherein said optional substituents are one to three R10 groups; 
A i R16B su svaki nezavisno odabrani od H i proizvoljno supstituirani C1-C8 alkil, ili zajedno s atomom dušika za kojega je vezan formira proizvoljno supstituiran hetero C3-C10 cikloalkil, pri čemu su navedeni nezavisni supstituenti jedna do tri R10 skupine;
The process of claim 6, wherein addition of hexane or heptane results in crystallization of a cyclic trimeric boronic acid anhydride of formula (XXIV): 
Postupak prema patentnom zahtjevu 55, naznačen time što dodavanje heksana ili heptana ima za rezultat kristalizaciju cilkličnog tripolimernog anhidrida organoborne kiseline formule (XXIV):
Compound of formula III displays excellent anti-diabetic efficacy reducing plasma glucose levels at all doses examined (42.7, 68.3, 96.1, and 109.3 % normalization). 
Spoj formule III pokazuje odličanu antidijabetičnu djelotvornost u smanjivanju razina glukoze u plazmi za sve ispitane doze (normalizacija: 42,7, 68,3, 96,1 i 109,3 %).
Example embodiments relate to composite materials, and in particular dental filling materials. 
Glavni aspekti izuma odnose se na Kompozitne materijale, posebice na materijale za dentalna punila.
Mass of Fibra-Cel is expressed in Kg 
Masa Fibra-Cel je izražena u kg.
This may be followed by removal of the cyano group by hydrolysis and decarboxylation, with the use of suitable protecting groups where necessary. 
Ovo može slijediti odstranjivanje cijano skupine hidrolizom i dekarboksilacija, s upotrebom prikladnih zaštitnih skupina gdje je potrebno.
In exemplary embodiments, the medicament is manufactured for the treatment of an autoimmune or inflammatory disease selected from the group consisting of rheumatoid arthritis, multiple sclerosis, proliferative lupus glomerulonephritis, inflammatory bowel disease (IBD), psoriasis, idiopathic thrombocytopenic purpura (ITP), Crohn's Disease and systemic lupus erythematosus (SLE), Hashimoto's thyroiditis, primary myxoedema, thyrotoxicosis/Graves disease, pernicious anaemia, autoimmune atrophic gastritis, autoimmune carditis, Addison's disease, premature menopause, type 1-diabetes mellitus, Good pasture's syndrome, myasthenia gravis, autoimmune haemolytic anaemia, idiopathic leucopenia, primary biliary cirrhosis, active chronic hepatitis (HBs Ag negative), cryptogenic cirrhosis, Sjogren's syndrome, dermatomyositis, scleroderma, mixed tissues connective disease, discoid lupus erythematosus, and systemic vasculitis. 
Protutijelo namijenjeno upotrebi u skladu s patentnim zahtjevom 3, naznačeno time što se autoimunu ili upalnu bolest bira iz skupine koju čine reumatoidni artritis, multipla skleroza, proliferativni lupus s glomerulonefritisom, upalna bolest crijeva (IBD), psorijaza, idiopatska trombocitopenična purpura (ITP), Crohnova bolest i sistemni eritematozni lupus (SLE), Hashimotoov tireoiditis, primarni miksoedem, tirotoksikoza/Gravesova bolest, perniciozna anemija, autoimuni atrofični gastritis, autoimuni karditis, Addisonova bolest, prijevremena menopauza, dijabetes melitus tip 1, Goodpastureov sindrom, mijastenija gravis, autoimuna hemolitična anemija, idiopatska leukopenija, primarna bilijarna ciroza, aktivni kronični hepatitis (HBs Ag negativni), kriptogena ciroza, Sjogrenov sindrom, dermatomiozitis, skleroderma, miješana bolest vezivnih tkiva, diskoidni eritematozni lupus, te sistemni vaskulitis.
The method according to Claim 1, characterized in that the contents carried by the channel state information further comprise: channel state indication information. 
Metoda sukladno zahtjevu 1, naznačena time što sadržaj prenošen kanalom stanja informacija nadalje obuhvaća: indikaciju informacije stanja kanala.
If no acyl addition was detected, an additional charge of reagents was done to try and start the reaction. 
Napredak rcakcije je bio nadziran pomoću TLC i/ili HPLC Ako nije detektirana acilna adicija, bilo je provedeno dodatno punjenje reagensom da bi se pokušala i započela reakcija.
reducing Compound 19 to produce Compound 18: wherein: 
(co) redukcije Spoja 19 kako bi se dobilo Spoj 18:
is selected from the group consisting of hydrogen, C1-C3 alkyl, C3-C6 cycloalkyl, C4-C5 alkylcycloalkyl, wherein C1-3 alkyl is optionally substituted with 1 to 3 substituents independently selected from halogen, hydroxy or C1-6 alkoxy; 
R, je izabran iz grupe koju čine vodik, C,-C3 alkil, Cs-Cg cikloalkil, C,-Cs alkilcikloalkil, gdje C;.3 alkil je izborno supstituiran sa 1 do 3 supstituenta nezavisno izabrana od halogena, hidroksi ili C,.4 alkoksi;
a CDRH2 sequence corresponding to amino acids 50 to 66 (YIDPYNGDTSYNQKFKG) of SEQ ID NO: 19, wherein one, two or three of said amino acids is optionally a different amino acid residue; 
(11) CDRH2 sekvencu koja odgovara aminokiselinama 50 do 66 (YIDPYNGDTSYNQKFKQG) iz SEK ID BR: 19, gdje jedna, dvije ili tri od spomenutih aminokiselina je po izboru različiti aminokiselinski ostatak;
said process comprising crystallizing compound of formula (IV) in a solvent comprising methyl isobutyl ketone to obtain a suspension, and 
CIVI, taj postupak obuhvaća: i) kristalizaciju spoja formule (IV) u otapalu koje sadrži metil izobutil keton radi dobivanja suspenzije, i 1i) "uklanjanje otapala iz suspenzije.
A genic expression adenoviral hybrid vector according to claim 6, wherein element iii is a tumor specific promoter selected from AFP, telomerase TERT, PAP, E2F and HIF. 
Adenovirusni hibridni vektor sa genskom ekspresijom prema patentnom zahtjevu 6, naznačen time što je element iii. tumor specifični promotor izabran od AFP, telomeraza TERT, PAP, F2F i HIF.
Method according to any of the previous claims, comprising the steps of shipping a box with first and second flaps closing the box, storing said box by exchanging the position of said first and second flaps, shipping again said box by returning first and second flaps to the original shipping position and closing the external flaps with adhesive tape. 
Uporaba kutije prema bilo kojem od prethodnih zahtjeva od 1 do 5, jednom ili više puta, prvo kao kutije za skladištenje s navedenim drugim preklopima (2) koji zatvaraju vanjski dio kutije, a potom kao kutije za transport s navedenim prvim preklopima (1) koji zatvaraju vanjski dio kutije, ili obrnutim redoslijedom.
a compensation container (73); 
kompenzacijski spremnik (73);
In the drawing: 
Na crtežima:
Press brake (1) according to the previous claim wherein the predetermined inner rim joint angle (a) is -20 to 20°, in particular -10 to 10°, in particular -5 to 5°, in particular -2 to 2°. 
Preša (1) prema prethodnom patentnom zahtjevu pri čemu prethodno određeni spojni kut (0) unutrašnjeg ruba je 20 do 20", naročito -10 do 10%, naročito -5 do 5%, naročito -2 do 2".
The method of claim 1, wherein the reaction is performed at a temperature between about -10°C and about -80°C in an ether for between about 12 and about 20 hours. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da se reakcija odvija na temperaturi između približno -10 °C do približno -80 °C u eteru između približno 12 do približno 20 sati.
Once the water injection and beverage production process is finished, the capsule tends to stay attached to these injection means. 
Kada se jednom završi postupak injektiranja vode i proizvodnje napitka, čahura nastoji ostati pričvršćene na to sredstvo za injektiranje.
A computer program product for translating addresses in a computing environment, the computer program product comprising: a computer readable storage medium readable by a processing circuit and storing instructions for execution by the processing circuit for performing a method according to any of claims 1 to 6. 
Proizvod računalni program za prevođenje adresa u računalno okruženje, proizvod računalni program obuhvaća: računalu čitljiv medij za pohranu čitljiv pomoću sklopa za procesiranje i uputa za pohranjivanje zbog izvršenja od strane sklopa za procesiranje zbog izvođenje metode u skladu s bilo kojim od patentnih zahtjeva 1 do 6.
The locking members 201 allow the user to operate the blender without requiring the constant application of force to the container (in order to keep the motor means switched on). 
Dio za pričvršćivanje 201 omogućuje korisniku da rukuje mješalicom bez potrebe stalnog pritiska na posudu (kako bi motor ostao uključen).
The method of claims 12 or 13 wherein said second protein of interest is an osmoprotective protein. 
Postupak u skladu s patentnim zahtjevom 12 ili 13, naznačen time, da je spomenuti drugi protein od interesa osmoprotektivni protein.
The PAL variant of item 9, wherein the variant is made by reacting AvPAL variant with NHS-activated polyethylene glycol at a ratio of 3 polyethylene glycol per lysine residue of the AvPAL variant. 
AVvPAL varijanta u skladu s patentnim zahtjevom 5, naznačena time, da se može dobiti reakcijom AvPAL varijante s polietilen glikolom aktiviranim NHS-om u omjeru 3 polietilenglikola po ostatku lizina AvPAL varijante.
The multi-armed polymer prodrug of claim 1, wherein the overall nominal average molecular weight of the prodrug ranges from 20,000 to 80,000 Daltons. 
Višestruko razgranati polimerni prolijek iz patentnog zahtjeva 1, pri čemu je ukupna prosječna molekulska masa prolijeka u rasponu od 20 000 do 80 000 Daltona.
The pharmaceutical composition according to any of claims 10 to 13, comprising peptides consisting of amino acid sequences according to SEQ ID No. 
Farmaceutski sastav sukladno bilo kojoj od tvrdnji 10 do 13, sadrži peptide koje sačinjavaju sljedovi amino kiselina sukladno SEQ ID br.
wherein R represents H or trimethylsilyl, R2 is as defined in formula (I) and R3 represents H or a suitable protecting group; with an aryl halide or triflate of formula (VI) 
(XI) gdje R predstavlja H ili trimetilsilil, R* je kako je definirano u formuli (1), a R* predstavlja H ili prikladnu zaštitnu grupu; sa aril halidom ili triflatom formule (VI)
is selected from hydrogen, (C1-C4)alkyl optionally substituted with hydroxy, (C1-C3)alkylamino or dimethylamino, (C1-C4)alkynyl optionally substituted with hydroxyl, and halo; 
je izabran iz grupe koju čine vodik, (C1-C4)alkil izborno supstituiran sa hidroksi, (C1-C3)alkilamino ili dimetilamino, (C1-C4)alkinil izborno supstituiran sa hidroksil i halo;
The formulation of the present invention comprises an aqueous carrier with a pH of 5.5 to 8.0 and a polypeptide comprising one or more single variable domains at a concentration of 120 mg/mL or more said formulation being formulated for administration to a human subject and said formulation further comprising buffer at a concentration of 10mM to 100mM selected from histidine pH 6.0-6-5, wherein said formulation has an inorganic salt concentration of 150 mM or lower and wherein the polypeptide comprises at least one single variable domain directed against human serum albumin (HSA). 
Formulacija koja sadrži vodeni nosač koji ima pH od 5.5 do 8.0 i polipeptid koji sadrži jednu ili više pojedinačnih varijabilnih domena u koncentraciji od 1 mg/mL do 200 mg/mL, navedena formulacija formulirana je za davanje ljudskom subjektu i navedena formulacija nadalje sadrži histidinski pufer u koncentraciji od 10 mM do 100 mM, pH 6.0-6.5; pri čemu navedena formulacija ima koncentraciju anorganske soli od 150 mM ili nižu, pri čemu je polipeptid odabran od jedne od SEQ ID NO: 1 do 6 i pri čemu pH formulacije iznosi između 6.2 i 7.5.
an annular handling device that can engage a first axial end of the manufacture to be closed by sewing or linking; 
- - prstenasti uređaj za rukovanje (2) koji je projektiran da zahvaća prvi aksijalni kraj (50a) gotovog proizvoda (50) koji treba zatvoriti šivanjem ili povezivanjem;
Evidently, said anchoring dowels are present on one side of either the upper (4) corrugated plate, the lower (5) corrugated plate, or even both, to anchor the joint profile in just one slab of the adjacent slabs. 
Kompenzacijski spoj prema bilo kojem od zahtjeva 3 do 5, naznačen time su gornje (4) i prve donje (5) valovite ploče u osnovi u istoj bočnoj ravnini.
68 75 A herbicide composition comprising as component (A) an herbicidally active amount of pelargonic acid and as component (B) at least one ALS inhibitor selected from the group consisting of iodosulfuron-methyl and foramsulfuron, wherein a weight ratio of components (A) and (B) is in a range from 30000:1 to 12.5:1, and wherein the composition is synergistically effective. 
Kombinacija herbicida koja sadrži kao komponentu (A) kaprilnu kiselinu i kaprinsku kiselinu u omjeru miješanja od između 65: 35 do 40:60 i kao komponentu (B) barem jedan ALS inhibitor sele odabran iz skupine herbicidno aktivnih sulfonilurea i sulfonamida, pri čemu je sulfonilurea iz komponente (B) odabrana iz skupine koju čine jodosulfuron-metil, foramsulfuron, mezosulfuron-metil, flazasulfuron, amidosulfuron i etoksisulfuron i sulfonamid iz komponente (B) je tienkarbazon-metil.
Compounds according to at least one of claims 1-4 in enantiomerically pure form and their salts, solvates or salts of solvates. 
-{[1-(2-kloro-3-fluoro-4-hidroksifenil)-3,3,3-trifluoro-2-hidroksi-2-(hidroksimetil)propil]amino}-7-fluoro-1H-kinolin-2-on i njihove soli, solvati ili soli solvata.
feeding said third off-gas to the off-gas treatment section wherein said finishing treatment section is adapted to treat said third off-gas with an acidic scrubbing liquid thereby forming a Ca-containing salt solution before recycling the scrubbing liquid to the urea ammonium nitrate section. 
protjecanje spomenutog CAN isparenog plina u sekciju završne obrade pri čemu je spomenuta sekcija završne obrade prilagođena kako bi obradila spomenuti CAN ispareni plin kiselom tekućinom za ispiranje time tvoreći otopinu soli koja sadrži Ca prije recikliranja tekućine za ispiranje u UAN sekciju.
Vacuum distillation apparatus for separating gold-silver alloys according to claim 1, characterised in that the restricting screen is made of high-melting metal, for instance titanium. 
Aparat za vakuum destilaciju za razdvajanje zlato-srebro legura u skladu sa patentnim zahtjevom 2, naznačen time što ograničavajuća pregrada (8) je napravljena od visoko-topljivog metala, na primjer titanija.
In preferred embodiments the bacterium is Listeria monocytogenes comprising a nucleic acid sequence encoding for expression by the bacterium of the EGFRvIII polypeptide sequences of the invention. 
Izolirana molekula nuklemske kiseline prema zahtjevu 5, naznačena time, da je molekula nukleinske kiseline kođon optimiran za ekspresiju u Listeria monocytogenes.
This creates considerable problems, due to the fact that extruded PMMA and crosslinked PMMA are visually indistinguishable, and for this reason any sorting aimed at separating the two types of substance would be difficult and unsafe. 
To stvara znatne probleme zbog činjenice što se ekstrudirani PMMA i umreženi PMMA vizualno ne razlikuju, i zbog toga bi bilo kakvo sortiranje, kojemu je cilj odvajanje ove dvije vrste tvari, bilo teško i beskorisno.
and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a heterocyclic ring Het1, in which 
R611 1R612, zajedno s i uključivši atom dušika na kojeg su vezani, tvore heterociklički prsten Hetl, gdje
wherein said adhesive is of a type that will allow said first and said second adhesive portions to separate and allow said napkin to be adhered to an object. 
pri čemu je navedeno ljepilo vrste koje će omogućiti navedenom prvom i navedenom drugom adhezivnom dijelu da se odvoje i omoguće navedenom ubrusu (100) lijepljenje za objekt.
2 is a longitudinal section of the lid at the point where it touches the cover of the internal opening from point A to B of FIG. 
Slika 2 prikazuje uzdužni presjek poklopca na mjestu gdje on dodiruje pokrov unutarnjeg otvora od točke A do B.